Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current standard of care for treatment to clear this bacteria. This research study is designed to determine the rate of clearance of this bacteria in healthcare workers who are carriers when using triple antibiotic ointment instead of mupirocin ointment.
Condition or disease
Nasal Carriers of Staphylococcus Aureus
Drug: Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Willing and able to give informed consent
Must have consented prior to registration for the study
concurrent treatment with antibiotics, topical or systemic
S. aureus decolonization attempt in prior six months
history of HIV
chemotherapy or systemic immunosuppressive therapy